145 related articles for article (PubMed ID: 20158047)
1. The effect of stealth liposomes on pharmacokinetics, tissue distribution and anti-tumor activity of oridonin.
Wang C; Wei Y; Yu L; Zhang L
PDA J Pharm Sci Technol; 2009; 63(5):409-16. PubMed ID: 20158047
[TBL] [Abstract][Full Text] [Related]
2. [The tissue distribution in mice and pharmacokinetics in rabbits of oridonin-solid lipid nanoparticles].
Zhang DR; Ren TC; Lou HX; Xing J
Yao Xue Xue Bao; 2005 Jun; 40(6):573-6. PubMed ID: 16144328
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
Xu Y; Meng H
Artif Cells Nanomed Biotechnol; 2016; 44(1):350-5. PubMed ID: 25162671
[TBL] [Abstract][Full Text] [Related]
4. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic effects of oridonin.
Tian L; Xie K; Sheng D; Wan X; Zhu G
BMC Complement Altern Med; 2017 Apr; 17(1):192. PubMed ID: 28376864
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
Chen G; Wang K; Yang BY; Tang B; Chen JX; Hua ZC
Int J Oncol; 2012 Jan; 40(1):139-47. PubMed ID: 21947421
[TBL] [Abstract][Full Text] [Related]
7. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of caspase-9 by oridonin, a diterpenoid isolated from Rabdosia rubescens, augments apoptosis in human laryngeal cancer cells.
Kang N; Cao SJ; Zhou Y; He H; Tashiro S; Onodera S; Qiu F; Ikejima T
Int J Oncol; 2015 Dec; 47(6):2045-56. PubMed ID: 26648189
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of freeze-dried long-circulation oridonin liposomes and their pharmacokinetics in rats].
Lin H; Qu C; Yu Y; Tang Y; Sun X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 42(6):638-43. PubMed ID: 24421229
[TBL] [Abstract][Full Text] [Related]
10. Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells.
Wang H; Ye Y; Pan SY; Zhu GY; Li YW; Fong DW; Yu ZL
Phytomedicine; 2011 Jan; 18(2-3):163-9. PubMed ID: 20724128
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and Antibacterial Derivatives of Oridonin: A Main Composition of Dong-Ling-Cao.
Li D; Han T; Xu S; Zhou T; Tian K; Hu X; Cheng K; Li Z; Hua H; Xu J
Molecules; 2016 Apr; 21(5):. PubMed ID: 27144553
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization, and Evaluation of Liposomes Containing Oridonin from
Wang Y; Wang M; Lin F; Zhang X; Zhao Y; Guo C; Wang J
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164121
[TBL] [Abstract][Full Text] [Related]
13. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
14. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells.
Wang S; Zhong Z; Wan J; Tan W; Wu G; Chen M; Wang Y
Am J Chin Med; 2013; 41(1):177-96. PubMed ID: 23336515
[TBL] [Abstract][Full Text] [Related]
15. Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling.
Xia R; Chen SX; Qin Q; Chen Y; Zhang WW; Zhu RR; Deng AM
Asian Pac J Cancer Prev; 2016; 17(2):667-71. PubMed ID: 26925661
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of oridonin-induced apoptosis in multiple myeloma cells.
Zhao J; Zhang M; He P; Zhao J; Chen Y; Qi J; Wang Y
Mol Med Rep; 2017 Apr; 15(4):1807-1815. PubMed ID: 28259901
[TBL] [Abstract][Full Text] [Related]
17. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
18. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens.
Hsieh TC; Wijeratne EK; Liang JY; Gunatilaka AL; Wu JM
Biochem Biophys Res Commun; 2005 Nov; 337(1):224-31. PubMed ID: 16176802
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
Allen TM; Hansen C
Biochim Biophys Acta; 1991 Sep; 1068(2):133-41. PubMed ID: 1911826
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor activity of oridonin nanosuspension.
Lou H; Zhang X; Gao L; Feng F; Wang J; Wei X; Yu Z; Zhang D; Zhang Q
Int J Pharm; 2009 Sep; 379(1):181-6. PubMed ID: 19563872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]